Diabetes medications and cardiovascular outcome trials: Lessons learned

被引：11

作者：

Patel, Kershaw V. ^{[1
]}

Rocha, Natalia de Albuquerque ^{[1
]}

McGuire, Darren K. ^{[1
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Cardiol, Dallas, TX USA

来源：

CLEVELAND CLINIC JOURNAL OF MEDICINE | 2017年 / 84卷 / 10期

关键词：

HEART-FAILURE; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; TYPE-2; SITAGLIPTIN; MELLITUS; INHIBITION; EXENATIDE; IMPROVES; COTRANSPORTERS;

D O I：

10.3949/ccjm.84gr.17006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The US Food and Drug Administration's current standards require that new diabetes medications demonstrate cardiovascular safety in large, long-term trials. New drugs that have been assessed in such trials are changing the management of type 2 diabetes.

引用

页码：759 / 767

页数：9

共 39 条

[1] Introduction
不详
[J]. DIABETES CARE, 2017, 40 : S1 - S130
[2] Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
Cherney, David Z. I.
Perkins, Bruce A.
Soleymanlou, Nima
Maione, Maria
Lai, Vesta
Lee, Alana
Fagan, Nora M.
Woerle, Hans J.
Johansen, Odd Erik
Broedl, Uli C.
von Eynatten, Maximilian
[J]. CIRCULATION, 2014, 129 (05) : 587 - 597
[3] CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis
Ferrannini, Ele
Mark, Michael
Mayoux, Eric
[J]. DIABETES CARE, 2016, 39 (07) : 1108 - 1114
[4] A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes
Frederich, Robert
Alexander, John H.
Fiedorek, Fred T.
Donovan, Mark
Berglind, Niklas
Harris, Susan
Chen, Roland
Wolf, Robert
Mahaffey, Kenneth W.
[J]. POSTGRADUATE MEDICINE, 2010, 122 (03) : 16 - 27
[5] Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, Jennifer B.
Bethel, M. Angelyn
Armstrong, Paul W.
Buse, John B.
Engel, Samuel S.
Garg, Jyotsna
Josse, Robert
Kaufman, Keith D.
Koglin, Joerg
Korn, Scott
Lachin, John M.
McGuire, Darren K.
Pencina, Michael J.
Standl, Eberhard
Stein, Peter P.
Suryawanshi, Shailaja
Van de Werf, Frans
Peterson, Eric D.
Holman, Rury R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03) : 232 - 242
[6] Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Heerspink, Hiddo J. L.
Perkins, Bruce A.
Fitchett, David H.
Husain, Mansoor
Cherney, David Z. I.
[J]. CIRCULATION, 2016, 134 (10) : 752 - 772
[7] The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats
Hocher, Berthold
Sharkovska, Yuliya
Mark, Michael
Klein, Thomas
Pfab, Thiemo
[J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (01) : 87 - 93
[8] Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2
Hummel, Charles S.
Lu, Chuan
Loo, Donald D. F.
Hirayama, Bruce A.
Voss, Andrew A.
Wright, Ernest M.
[J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2011, 300 (01): : C14 - C21
[9] Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Inzucchi, Silvio E.
Bergenstal, Richard M.
Buse, John B.
Diamant, Michaela
Ferrannini, Ele
Nauck, Michael
Peters, Anne L.
Tsapas, Apostolos
Wender, Richard
Matthews, David R.
[J]. DIABETES CARE, 2015, 38 (01) : 140 - 149
[10] Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial
Kaku, K.
Enya, K.
Nakaya, R.
Ohira, T.
Matsuno, R.
[J]. DIABETES OBESITY & METABOLISM, 2015, 17 (07) : 675 - 681

← 1 2 3 4 →